Company Profile

With a focus of women’s health and initial areas of interest to include recurrent urinary tract infections and bacterial vaginosis, Osel, Inc., a privately held biotechnology company, is organized around a new class of medicine: Live Biotherapeutic Products (LBPs) that prevent or treat medical conditions resulting from a disruption of the human microbiome. A pioneer in the field of LBPs. Osel was among the first companies to receive U.S. Food and Drug Administration authorization to test a live bacterial therapeutic. The company’s proprietary approach identifies differences between healthy and disease-related microbiomes and leverages beneficial microbes to treat problematic disruptions or dysbioses. Osel’s approach repopulates the disrupted microbiome with beneficial bacteria that help restore a healthy and protective microbiota. With a focus on Gastrointestinal (“GI”) Disorders, and Infectious Diseases through modulation of the Human Microbiome, Osel Inc. is developing genetically modified vaginal lactobacillus. The company focuses on mucosal microflora by identifying the naturally occurring bacteria to treat and prevent diseases caused by disruptions in the protective microflora; and developing technologies to genetically enhance the capabilities of these bacteria to combat disease-causing organisms. Osel Inc. is developing CBM588 that prevents C. difficile-associated disease and the incidence of antibiotic associated diarrhea; and LACTIN-V to preventive vaginal yeast infections which occur